SQZ Biotechnologies Company (SQZB)

Market Cap	825.75K
Revenue (ttm)	12.12M
Net Income (ttm)	-71.64M
Shares Out	29.49M
EPS (ttm)	-2.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120
Average Volume	1,488
Open	0.0280
Previous Close	0.0280
Day's Range	0.0280 - 0.0280
52-Week Range	0.0210 - 0.1160
Beta	1.40
RSI	42.82
Earnings Date	May 9, 2025

About SQZB

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 53
• Stock Exchange: OTCMKTS
• Ticker Symbol: SQZB

Financial Performance

In 2022, SQZB's revenue was $21.48 million, a decrease of -20.74% compared to the previous year's $27.10 million. Losses were -$79.46 million, 15.6% more than in 2021.